BioRestorative Therapies Reports Q1 2026 Financial Results with Revenue Decline and Improved Net Loss

BioRestorative Therapies, Inc. reported its financial results for the first quarter of 2026, revealing total revenues of $23,170, a decrease from $25,000 in the same period last year. The revenue breakdown included $11,870 from product sales, specifically from the newly launched BioX product line, and $11,300 from royalty revenue, which saw a significant decline of 54.8% compared to the previous year. This drop in royalty revenue was attributed to a decrease in disc procedures performed by its sublicense partner, the Stem Cell Treatment Company (SCTC).

The company’s operating expenses for the quarter were $3,401,518, down from $4,829,625 in the prior year, primarily due to reduced research and development costs and lower general and administrative expenses. The net loss for the quarter was $2,154,405, a notable improvement from the $5,339,799 loss reported in the first quarter of 2025. This reduction in losses was supported by a gain of $1,220,121 from the change in fair value of warrant liabilities, reflecting a favorable adjustment following the reclassification of these liabilities to equity.

In terms of liquidity, BioRestorative Therapies reported cash and cash equivalents of $3,112,679 as of March 31, 2026, a significant increase from $1,511,188 at the end of 2025. The company also experienced a substantial improvement in working capital, moving from a deficiency of $586,029 to a positive working capital of $2,185,071. This change was largely driven by a reduction in current liabilities following the conversion of Series B Preferred Stock and a successful public offering that generated approximately $5 million in gross proceeds.

Strategically, the company has made significant advancements, including the commercial launch of its BioX product line and the completion of a public offering that included the issuance of common stock and pre-funded warrants. Additionally, BioRestorative Therapies is actively pursuing its clinical development programs, including the Phase 2 trial for its lead product candidate, BRTX-100, aimed at treating chronic lower back pain. However, the company faces challenges, including the need for ongoing financing to support its operations and development plans, as well as compliance with Nasdaq listing requirements due to its stock price falling below the minimum bid price.

Looking ahead, BioRestorative Therapies anticipates continued net losses and negative cash flows as it executes its development plans. The company has expressed concerns regarding its ability to sustain operations without additional financing, which may impact its strategic initiatives and overall business viability.